Download PDF
J Neurol Surg A Cent Eur Neurosurg 2013; 74(S 01): e58-e61
DOI: 10.1055/s-0032-1330112
Case Report
Georg Thieme Verlag KG Stuttgart · New York

Stevens Johnson Syndrome—An Adverse Drug Reaction Occurred after Uncomplicated Removal of an Intracerebral Cavernous Hemangioma

Reza Akhavan-Sigari
1   Department of Neurosurgery, University Medical Center Göttingen, Georg-August-University Göttingen, Germany
2   Department of Neurosurgery, Imam Reza University, Razavi Hospital, Mashhad, Iran
,
Veit Rohde
1   Department of Neurosurgery, University Medical Center Göttingen, Georg-August-University Göttingen, Germany
,
Mehdi Abili
2   Department of Neurosurgery, Imam Reza University, Razavi Hospital, Mashhad, Iran
› Author Affiliations
Further Information

Publication History

01 September 2011

02 March 2012

Publication Date:
14 January 2013 (online)

    Permissions and Reprints

Abstract

Background Toxic epidermal necrolysis (TEN) is a rare, severe adverse drug reaction. Steven-Johnson syndrome (SJS) represents the milder end of the spectrum. The exact pathogenesis of TEN and SJS is still unknown. Many drugs, including prednisolone, cyclosporin, and intravenous immunoglobulin (IVIG), have been used in an attempt to halt the disease process. The use of phenytoin as a prophylactic anticonvulsant after brain surgery, particularly for brain tumors, is a common practice, regardless of whether the patient has a previous history of convulsions. This treatment policy assumes that the benefits exceed the risks.

Case In this paper, we describe a young patient who underwent a total removal of an intracerebral cavernous hemangioma following development of SJS after taking phenytoin postoperatively.

Conclusion We suggest that the practice of routine use of phenytoin following brain surgery should be re-evaluated because the treatment may be neither essential nor without side effects.

Keywords

Phenytoin - Steven-Johnson syndrome - adverse drug reaction
 

  • References

  • 1 WHO. International drug monitoring: the role of national centres. Tech Rep Ser WHO 1972; , no 498
    PubMedGoogle Scholar
  • 2 Rawlins M, Thompson W. Mechanisms of adverse drug reactions. In: Davies D, , ed. Textbook of Adverse Drug Reactions. New York: Oxford University Press; 1991: 18-45
    Google Scholar
  • 3 Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356 (9237) 1255-1259
    Google Scholar
  • 4 Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5 (4) 309-316
    CrossrefPubMedGoogle Scholar
  • 5 Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Arch Pediatr Adolesc Med 1922; 24 (6) 526-533
    CrossrefPubMedGoogle Scholar
  • 6 Habif TP. Clinical Dermatology. 3rd ed. St Louis: Mosby-Year Book; 1996: 570-572
    Google Scholar
  • 7 Donta-Bakoyianni K, Mitsea AG, Deodoropoulou-Papadimitriou K. Stevens-Johnson syndrome: case presentation. J Clin Pediatr Dent 2002; 27 (1) 71-76
    PubMedGoogle Scholar
  • 8 Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC. SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138 (8) 1019-1024
    CrossrefPubMedGoogle Scholar
  • 9 Rzany B, Mockenhaupt M, Baur S , et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49 (7) 769-773
    CrossrefPubMedGoogle Scholar
  • 10 Roujeau J-C, Kelly JP, Naldi L , et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333 (24) 1600-1607
    CrossrefPubMedGoogle Scholar
  • 11 Mockenhaupt M, Viboud C, Dunant A , et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128 (1) 35-44
    CrossrefPubMedGoogle Scholar
  • 12 Cotter JB. Methazolamide-induced Stevens-Johnson syndrome: a warning!. Arch Ophthalmol 1998; 116 (1) 117
    CrossrefPubMedGoogle Scholar
  • 13 Tay YK, Huff JC, Weston WL. Mycoplasma pneumoniae infection is associated with Stevens-Johnson syndrome, not erythema multiforme (von Hebra). J Am Acad Dermatol 1996; 35 (5 Pt 1) 757-760
    CrossrefPubMedGoogle Scholar
  • 14 Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med 2011; 57 (2) 115-119
    CrossrefPubMedGoogle Scholar
  • 15 Kroonen LM. Erythema multiforme: case report and discussion. J Am Board Fam Pract 1998; 11 (1) 63-65
    PubMedGoogle Scholar
  • 16 Guibal F, Bastuji-Garin S, Chosidow O, Saiag P, Revuz J, Roujeau JC. Characteristics of toxic epidermal necrolysis in patients undergoing long-term glucocorticoid therapy. Arch Dermatol 1995; 131 (6) 669-672
    CrossrefPubMedGoogle Scholar
  • 17 Paul C, Wolkenstein P, Adle H , et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134 (4) 710-714
    CrossrefPubMedGoogle Scholar